Full Press Release Details
Tiziana Life Sciences to participate in a Fireside
on 28 April 2021 at 10:30 a.m. EDT
NEW YORK and LONDON - 27 April 2021 (GLOBE
NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO
and CSO Dr. Kunwar Shailubhai and the chair of its Scientific Advisory Committee, Dr Howard Weiner, will participate in a fireside chat
via a video link on Wednesday, 28 April 2021 at 10:30 a.m. EDT (US and Canada) to provide updates on the Company. Please note that only
information which is already in the public domain will be discussed.
| Date: | Wednesday, 28 April 2021 |
| Time: | 10:30 a.m. - 11:00 a.m. Eastern Daylight Savings Time (US and Canada) |
| Webcast: | https://www.webcaster4.com/Webcast/Page/2433/41045 |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition
to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody
in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases,
such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin
6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19
For further enquiries:
United Kingdom Investors:
United States Investors: